.png)
Mid-size Biopharmaceutical
HEOR, Market Access
Launched
Rare Cardiovascular Disease
Subscribe to our newsletter to receive the latest case studies.
Mid-size Biopharmaceutical
HEOR, Market Access
Launched
Rare Cardiovascular Disease
A mid-size biopharmaceutical company had reached a major regulatory milestone for a novel cardiovascular therapy.
Despite strong clinical differentiation, early payer discussions raised a concern: U.S. uptake could stall without a clear, payer-relevant value narrative.
The client engaged Alkemi to validate the most compelling value drivers, refine a differentiated U.S. payer story, and equip teams with tools to support adoption in a rapidly evolving market.
1. Reviewed global value propositions, U.S. value assessments, and competitive dynamics to identify gaps in payer-relevant claims.
2. Conducted payer, IDN decision-maker, and clinician interviews to prioritize and pressure-test clinical and economic value drivers.
3. Developed a U.S. payer value story grounded in evidence and aligned to payer decision-making needs.
4. Translated the narrative into field-ready tools and trained cross-functional teams to support consistent execution.
Make differentiation land with U.S. payers and make it usable in the field.
“Following our recent payer discussions, I wanted to share how impactful Alkemi’s work has been. The work made a noticeable difference in how our story landed.” - Senior Market Access Lead
Teams were equipped with a validated, U.S.-specific narrative grounded in evidence.
The value story strengthened positioning in a crowded and evolving market.
Cross-functional teams aligned on messaging and execution to support adoption.